Displaying drugs 11026 - 11050 of 11622 in total
Pidacmeran
Pidacmeran is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults).
Investigational
Matched Description: … Pidacmeran is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and …
Bifidobacterium Longum Infantis 35624
Bifidobacterium Longum Infantis 35624 is a probiotic being investigated for the treatment of gastrointestinal disorders, such as Crohn's disease and irritable bowel syndrome.[A259872, A259877]
Investigational
Matched Description: … Bifidobacterium Longum Infantis 35624 is a probiotic being investigated for the treatment of gastrointestinal …
Emrusolmin
Emrusolmin restores hippocampal synaptic and transcriptional plasticity as well as spatial memory in a mouse model for Alzheimer's disease, when given orally before or after the onset of pathology.
Experimental
Matched Description: … Emrusolmin restores hippocampal synaptic and transcriptional plasticity as well as spatial memory in a …
Rovafovir etalafenamide
Rovafovir etalafenamide is under investigation in clinical trial NCT03472326 (Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen).
Investigational
Matched Description: … clinical trial NCT03472326 (Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a …
Brimapitide
Brimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers).
Investigational
Matched Description: … Brimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single …
TERN-101
TERN-101 is under investigation in clinical trial NCT04328077 (LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH)).
Investigational
Matched Description: … TERN-101 is under investigation in clinical trial NCT04328077 (LIFT Study: A Safety, Tolerability, Efficacy …
ORP-101
ORP-101 is under investigation in clinical trial NCT04129619 (A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)).
Investigational
Matched Description: … ORP-101 is under investigation in clinical trial NCT04129619 (A Comparison of the Effects of ORP-101 …
Favezelimab
Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)).
Investigational
Matched Description: … Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and …
BN‐Brachyury vaccine
BN‐Brachyury vaccine is a novel prime‐boost therapeutic cancer immunotherapy. It is composed of the MVA-BN-brachyury-TRICOM vaccine and the fowlpox virus(FPV)‐Brachyury booster vaccine.
Investigational
Matched Description: … BN‐Brachyury vaccine is a novel prime‐boost therapeutic cancer immunotherapy. …
HMI-203
HMI-203 is an investigational gene therapy developed by Homology Medicines, Inc. It consists of a recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate-2-sulfatase (hIDS).
Investigational
Matched Description: … It consists of a recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate …
Licofelone
Developed by the German pharmaceutical company, Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and Lacer, licofelone (ML3000) is a dual COX/LOX inhibitor and the first member of this new class of analgesic and anti-inflammatory drugs. It is currently under evaluation as a treatment for osteoarthritis (OA), the most common...
Investigational
Matched Description: … Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and Lacer, licofelone (ML3000) is a ... It is currently under evaluation as a treatment for osteoarthritis (OA), the most common form of arthritis …
PYM50018
PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in...
Investigational
Matched Description: … PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. ... When administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle …
Technetium Tc-99m ciprofloxacin
99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging agent for the potential diagnosis of infection, including fever of unknown origin, osteomyelitis, wound infection, abdominal abscess, pneumonia, appendicitis and tuberculosis. INFECTON combines the widely used antibiotic, ciprofloxacin, with Technetium ((99m)Tc), the most commonly used radioisotope in...
Investigational
Matched Description: … 99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging …
Plozalizumab
Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes. Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to...
Investigational
Matched Description: … Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found ... The recruitment of macrophages to the arterial wall is believed to be a critical step in the development …
SYNB1020
SYNB1020 is an engineered strain of Escherichia coli Nissle 1917 developed by Synlogic Inc. It was initially designed to convert ammonia to L-arginine and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016; however, the manufacturer discontinued further development of SYNB1020 to treat...
Investigational
Matched Description: … lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study. ... however, the manufacturer discontinued further development of SYNB1020 to treat hyperammonemia due to a …
Vasomera
Investigational
Volixibat
Volixibat, also known as SHP626 or LUM002, is an investigational drug that will potentially be used for the treatment of Non-Alcoholic Steatohepatitis (NASH). If approved for use, it will be the first available agent for the treatment of NASH.
Volixibat is a selective inhibitor of the apical sodium-dependent bile acid...
Experimental
Investigational
Matched Description: … Volixibat is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT), a transmembrane ... Inhibiting this enzyme results in a decrease of bile acids returning to the liver, which is helpful for ... granted fast track status by the Food and Drug Administration due to promising initial results and a …
Rhamnose
A methylpentose whose L- isomer is found naturally in many plant glycosides and some gram-negative bacterial lipopolysaccharides. [PubChem]
Experimental
Matched Description: … A methylpentose whose L- isomer is found naturally in many plant glycosides and some gram-negative bacterial …
V24343
The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.
Investigational
Matched Description: … The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's …
MBT-0312
MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.
Investigational
Matched Description: … MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving …
Denibulin
Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.
Investigational
Matched Description: … Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment …
NS-398
NS-398 is a COX-2 inhibitor. It was developed as part of the mechanistic study of the cyclooxygenases.
Experimental
Matched Description: … NS-398 is a COX-2 inhibitor. …
PF-5190457
PF-5190457 is under investigation in clinical trial NCT01522807 (A Study Of Three PF-05190457 Formulations In Healthy Volunteers).
Investigational
Matched Description: … PF-5190457 is under investigation in clinical trial NCT01522807 (A Study Of Three PF-05190457 Formulations …
Pexastimogene devacirepvec
Pexastimogene devacirepvec is under investigation in clinical trial NCT00429312 (A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma).
Investigational
Matched Description: … Pexastimogene devacirepvec is under investigation in clinical trial NCT00429312 (A Study of Recombinant …
JBPOS0101
JBPOS0101 is under investigation in clinical trial NCT03976076 (A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients).
Investigational
Matched Description: … JBPOS0101 is under investigation in clinical trial NCT03976076 (A Study of Orally Administered JBPOS0101 …
Displaying drugs 11026 - 11050 of 11622 in total